CRM Publications

Brosnan MJ, Devlin AM, Clark JS, Mullins JJ, Dominiczak AF.  1999.  Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27.Am J Hypertens. 12(7):724-31.

Montgomery HE, Kiernan LA, Whitworth CE, Fleming S, Unger T, Gohlke P, Mullins JJ, McEwan JR.  1998.  Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27.J Hypertens. 16(5):635-43.

Clark AF, Sharp MG, Mullins JJ.  1996.  Gene targeting and its application to basic hypertension research.Clin Sci (Lond). 90(6):435-46.

Sharp MG, Fettes D, Brooker G, Clark AF, Peters J, Fleming S, Mullins JJ.  1996.  Targeted inactivation of the Ren-2 gene in mice.Hypertension. 28(6):1126-31.

Brosnan MJ, Mullins JJ.  1993.  Transgenic animals in hypertension and cardiovascular research.Exp Nephrol. 1(1):3-12.

Barrett GL, Mullins JJ.  1992.  Studies on blood pressure regulation in hypertensive ren-2 transgenic rats.Kidney Int Suppl. 37:S125-8.

Barrett G, Mullins JJ.  1992.  Transgenic animal models of cardiovascular disease.Curr Opin Biotechnol. 3(6):637-40.

Bachmann S, Peters J, Engler E, Ganten D, Mullins JJ.  1992.  Transgenic rats carrying the mouse renin gene--morphological characterization of a low-renin hypertension model.Kidney Int. 41(1):24-36.

Ganten D, Takahashi S, Lindpaintner K, Mullins JJ.  1991.  Genetic basis of hypertension. The renin-angiotensin paradigm.Hypertension. 18(5 Suppl):III109-14.